



















It is currently estimated that around 194 million people 
have diabetes mellitus (DM) in the adult population.1 
The prevalence of type 2 DM differs widely in 
different South African population groups. Previous 
studies have indicated a prevalence of 28.7% in a 
mixed population in Cape Town, 13% among Indians 
in Durban and 8% in urban blacks in Cape Town.2 
Especially pertinent to our health care environment is 
that the diagnosis is often made only with the advent 
of a cardiovascular, cerebral or metabolic event, with 
one or more microvascular complications already 
present.  Multifactorial aetiologies can be ascribed to 
the latter, one critical reason being that DM is usually 
asymptomatic in its early stages. Type 2 DM is usually 
only recognised 5 - 12 years after hyperglycaemia 
develops.3  
Compared with the general population, morbidity and 
mortality rates from coronary artery disease (CAD) are 
two to fourfold higher among patients with type 2 DM 
and impaired glucose tolerance (IGT).4 In a research 
study5 that assessed mortality associated with the 
American Diabetic Association (ADA) fasting glucose 
criteria compared with the World Health Organization 
(WHO) 2-hour glucose criteria, researchers concluded 
that abnormalities in 2-hour glucose values are better 
predictors of mortality than fasting glucose when 
applied alone in screening. Others,6 however, state 
that the oral glucose tolerance test (OGTT) is poorly 
reproducible and that measurement of glycosylated 
haemoglobin (HbA1c) levels represents a reasonable 
approach in  identifying treatment-requiring DM. 
In South Africa, studies done on different ethnic 
groups show varying prevalence rates. The prevalence 
of DM and IGT in elderly coloured South Africans was 
found to be 28.7% and 15% respectively.7 A study8 
done on Xhosa factory workers in Transkei showed 
an age-adjusted prevalence of 4.5% and 5.1% for DM 
and IGT respectively. In a 10-year follow-up study of 
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South African Indian subjects, at baseline, the crude 
prevalences of DM and IGT were found to be 9.8% and 
5.8% respectively.9 Screening a group of Zulu subjects 
for DM revealed a prevalence of 5.3% for DM and 7.7% 
for IGT when adjusted for age and sex.10 In the surveys 
conducted in populations in sub-Saharan Africa there 
was considerable variation in the categorisation of 
individuals using the ADA and old WHO criteria. 
The level of agreement between the two ranged 
from fair to good (kappa statistic 0.71 - 0.86).11 Also, 
the prevalence of impaired fasting glycaemia (IFG) 
was lower than that of IGT in 10 of the surveys and 
the agreement was fair, with kappa ≤ 0.26 in all the 
surveys.11 
In a prospective study12 of glucose metabolism in 
patients with acute myocardial infarction and no 
previous diagnosis of DM, the patients had their 
glucose concentrations recorded during hospitalisation 
and a standardised OGTT was done at discharge 
and again at 3-month follow-up. Their results 
indicated that previously undiagnosed DM (25% at 
3 months) and IGT (40% at 3 months) are common 
in patients with an acute myocardial infarction and 
that these abnormalities can be detected early in the 
postinfarction period. 
Often the diagnosis of type 2 DM is made on a 
measurement of fasting hyperglycaemia only.  The 
aim of the current study was to explore the ability of 
other variables such as HbA1c, ADA score, measures 
of the metabolic syndrome (waist circumference, 
high-density lipoprotein (HDL), and triglycerides) to 
predict an initial diagnosis of DM or abnormal glucose 
tolerance (a combination of IGT and the diabetic 
glucose tolerance groups) based on the WHO criteria 




Patients with a high index of suspicion of CAD 
(positive exercise tolerance or positive pyridamole 
stress test) referred for elective coronary angiograms 
and those admitted for elective interventions to the 
cardiology or medical wards and the coronary care 
unit were included. Self-reported previous diagnosis 
of DM and use of antidiabetic agents were the only 
exclusion criteria. The University of Pretoria Ethics 
Committee approved the study in August 2002 and 
informed consent was obtained from each participant. 
Patient recruitment commenced in September 2002 
and was completed in May 2003.
Design and measurements
A cross-sectional study was undertaken involving 
120 consecutive patients. After an overnight fast 
of 10 hours, venepuncture was done for fasting 
plasma glucose (FPG), fasting lipogram and HbA1c. 
The lipogram and the HbA1c were measured using 
the Beckman Coulter (Beckman Coulter, Midrand, 
Gauteng), while glucose values were measured with 
the Beckman LX 20 (Beckman Coulter).  After initial 
blood samples were collected, a 2-hour glucose 
test using a 75 g glucose load (consumed within 10 
minutes) was done and this test served as the gold 
standard. Demographic variables including age, 
ethnic group, weight, height and blood pressure 
were recorded. Waist circumference was measured 
on all participants and the measurement was taken 
as the centre point of the distance between the last 
intercostal rib and the superior iliac spine. Patients 
were also asked to complete a questionnaire that 
included 7 items, viz. (i) women who delivered a 
macrosomic baby; (ii) one or more siblings with DM; 
(iii) one or more parents with DM; (iv) body mass 
index (BMI) ≥ 27 kg/m2; (v) age < 65 and little or no 
physical activity in most weeks; (vi) age 45 - 64; and 
(vii) age ≥ 65 to score the ADA questionnaire test.13 
Items i to iii were worth 1 point each,  items iv to vi 
5 points each and item vii 9 points.  Subjects with a 
total ≥ 10 points were considered to have a positive 
screening test.
The following diagnostic criteria were used. DM, 
IFG and normal fasting glucose (NFG) were defined 
according to the new ADA criteria.14 NFG was 
classified as fasting glucose < 5.6 mmol/l, and IFG 
as fasting glucose ≥ 5.6 mmol/l but < 6.9 mmol/l. The 
diagnosis of diabetes was made on a fasting glucose 
≥ 7.0 mmol/l. Using the WHO criteria, DM was defined 
as a 2-hour glucose ≥ 11.1 mmol/l, IGT as fasting 
glucose < 7.0 mmol/l and 2-hour glucose ≥ 7.8 mmol/l, 
normal glucose tolerance (NGT) as fasting glucose 
< 6.1 mmol/l and 2-hour glucose < 7.8 mmol/l. The 
category of impaired fasting glycaemia based on the 
WHO classification of a fasting glucose ≥ 6.1 mmol/l 
but < 7.0 mmol/l and 2-hour glucose < 7.8 mmol/l 
was not used in this study.  The category of abnormal 
glucose tolerance was defined as IFG, IGT and DM 
based either on the ADA or WHO criteria.  
Statistical analysis
All statistical calculations were done using Stata 
version 8.0. Baseline characteristics were compared 
in 3 groups as classified by the WHO criteria.  
Continuous data were compared using the Kruskal-
Wallis test and proportions were compared using the 
chi-square test. The kappa statistic was calculated to 
assess the agreement between the 2 criteria. Owing to 
the relatively few cases with DM, multivariate models 
were not estimated to predict DM and only univariate 
models were evaluated. For abnormal glucose 
tolerance (IFG, IGT or DM) multivariate models were 
evaluated with univariate predictors that had p-values 
< 0.25. The models were constructed based on: (i) only 
demographic variables (ethnic group, age); (ii) the 
latter plus lipid measures (HDL and triglycerides); (iii) 




















the latter plus HbA1c; and (iv) demographic variables 
plus HbA1c. Models were evaluated with Hosmer-
Lemeshow goodness of fit tests and diagnostic ability 
(sensitivity, specificity, predictive value and receiver 
operating characteristic (ROC) curves). The various 
ROC curves were compared non-parametrically 
(no adjustment was made for multiple testing). p-
values less than 0.05 were regarded as statistically 
significant. 
Results
The participants comprised 9 blacks (7.5%), 13 Indians 
(10.8%), 5 coloureds  (4.2%) and 93 whites (77.5%). 
The overall mean age was 58 years, with 37 subjects 
(30.8%) being female and 83 (69.2%) male. Other 
characteristics are shown in Table I.
The distribution of the 120 participants by glucose 
concentrations and their classifications according to 
the 2 sets of criteria are shown in Table II. While the 
ADA criteria diagnosed 95 subjects (79.1%) as normal, 
the WHO criteria only classified 65 (54.2%) as having 
normal glucose tolerance. The prevalence of DM 
according to the WHO criteria was 11.7%; in contrast 
the ADA criteria diagnosed only 5 subjects, with a 
prevalence of 4.2%.  
A poor agreement exists between the criteria, as the 
kappa value was 0.26 (p < 0.00001).
Predicting diabetes mellitus
As shown in Table II, only 14 subjects were diagnosed 
as having DM according to the criteria used. This 
was deemed unsatisfactory for multivariate logistic 
regression and only univariate logistic regression 
was done.15 The 2-hour glucose value predicted 
diabetes 100% correctly in this sample (all subjects 
with diabetic fasting values also had diabetic 2-hour 
values). The univariate associations with DM are given 
in Table III. HbA1c was the only statistically significant 
predictor.
Predicting abnormal glucose 
tolerance
Details are given in Fig. 1 and Table IV. The variable 
ethnic group was classified into 2 groups, with whites 
and blacks collectively as the reference group and 
the other 2 groups (coloureds and Indians) as the 
risk group.  The motivation for this classification 
was evident after the completion of tabular analysis 
revealed that abnormal glucose homeostasis was far 
more common in the Indians and coloureds. Even 
though the number of Indians (N = 13) and coloureds 
(N = 5) was relatively small, the frequency of IGT was 
77% and 80% respectively, while in the blacks IGT 
frequency was 44% and in whites 40%. Statistics of 
the univariate variables for abnormal glucose tolerance 
are given in Table IV.
The multivariate models are shown in Table V and Fig. 
1. The basic model (model 1) using only ethnic group 
and age yielded an AUC of 0.66 (66% of individuals 
would be correctly classified using ethnic group and 
age). Adding lipid parameters (model 2) to the basic 
model improved the AUC from 0.66 to 0.75  
(p = 0.05) (Fig. 1). Likewise, adding HbA1c to the basic 
model (model 4) improved the AUC from 0.66 to 0.74 
(p = 0.046). When HbA1c and lipids were both added 
to the basic model (model 3) increases in the AUC 
of the ROC, and in sensitivity and specificity were 
minimal. The p-value for comparing the ROC curves 
for model 2 (AUC of 0.75) versus model 3 (AUC of 0.79) 
was 0.14. Although significant as univariate variables, 
when included in the basic model and dropped 
stepwise with the aid of the likelihood ratio test, body 
mass index (BMI), waist circumference and ADA 
scores were shown to be non-contributory (p-value of 
likelihood ratio test > 0.05). On evaluating leverage 
and outliers, 2 observations with high leverage were 
identified. Deleting the outliers improved the AUC 
from 0.74 to 0.76 for model 4 and from 0.75 to 0.78 for 
model 2. 
      
Variable   




Waist circumference (cm)    
LDL (mmol/l)      
HDL (mmol/l)        
Cholesterol (mmol/l)              
Triglycerides (mmol/l)       
HbA1c (%)    
FPG (mmol/l)  
ADA score  
BP  = blood pressure; BMI = body mass index; LDL = low-density lipoprotein, HDL = high-density lipoprotein, cholesterol = total cholesterol, FPG = fasting plasma glucose; 
ADA = American Diabetic Association.    




































































Optimal cut-off values for fasting 
glucose and HbA1c given the reference 
test (OGtt)
Currently, according to the ADA criteria a fasting 
glucose of 5.6 mmol/l is considered diagnostic of DM. 
Coincidentally in this study a value of 5.6 mmol/l 
yielded a prevalence of 4.2% only, as shown in 
Table II. Will lowering the cut-off value of 5.6 mmol/l 
improve the diagnostic value of the fasting glucose 
concentration? Adopting the OGTT as the gold 
standard and using ROC analysis an ‘optimal’ cut-off/
score for fasting glucose and HbA1c was determined. 
‘Optimal’ is meant only in the sense that it indicates 
the value of the new diagnostic test yielding the 
highest combination of sensitivity and specificity. 
For fasting glucose, the optimal value was 5.6 mmol/l 
with a sensitivity of 85.7% (95% CI: 57.29 - 98.2) and 
specificity of 87.7% (95% CI: 79.9 - 93.3). For HbA1c it 
was 5.3% with a sensitivity of 71.4% (95% CI: 41.9 - 
91.6) and specificity of 67.9% (95% CI: 58.1 - 76.7).  
Discussion
In a clinical situation diagnosing DM means 
much more than making a biochemical diagnosis. 
It encompasses managing hyperglycaemia and 
hyperlipidaemia, hypertension and obesity (if present). 
Diagnosing DM as soon as possible after admission is 
important.  With the implementation of a simplified 
approach to diagnosing DM, it is envisaged that an 
increasing number of patients who need treatment 
will be identified to prevent the development and 
progression of this disease.
In this study, a significant number of patients (9 out 
of 14) would not have been detected if the OGTT had 
not been performed. Also the IFG category included 
substantially fewer people than the IGT category, i.e. 
20 (16.7%) compared with 41 (34.2%).   
This study did not demonstrate differences in findings 
on coronary arteriography between subgroups 
according to glucose tolerance.
It has been stated previously that the OGTT is not 
performed frequently in the clinical setting.  Apart 
from being deemed poorly reproducible, it is described 
as inconvenient to administer and unpleasant for 
patients, and must be performed twice to confirm the 
   confidence
Variable Odds ratio p-value   interval
Age       1.02    0.18   0.99 - 1.06
Gender       1.41    0.39   0.65 - 3.08
Ethnic group       4.43    0.01  1.37 - 14.40
Systolic BP       1.00    0.61   0.98 - 1.02
Diastolic BP       1.01    0.49   0.98 - 1.05
Body mass index       1.06    0.18   0.97 - 1.15
Waist circumference       1.03    0.09   0.91 - 1.06
LDL cholesterol       1.11    0.60   0.74 - 1.67
HDL cholesterol       0.32    0.08   0.87 - 1.15
Total cholesterol       1.17    0.32   0.85 - 1.61
Triglycerides       4.86    0.00  1.79 - 13.25
HbA1c       2.46    0.00   1.23 - 4.91
ADA score       1.08    0.11   0.98 - 1.20
BP = blood pressure; LDL = low-density lipoprotein; HDL = high-density 
lipoprotein; ADA = American Diabetic Association.
table iV.     Univariate odds ratios of predictors 
for abnormal glucose tolerance 
WHO  NFG iFG DFG 
criteria (N = 95) (N = 20) (N = 5) total %
NGT 
(N = 65)       61      4      0 54.2
IGT  
(N = 41)      32      9      0 34.2
DGT
(N = 14)        2      7      5 11.7
   Total %     79.1   6.7     4.2 
NGT = normal glucose tolerance; IGT = impaired glucose tolerance; DGT = 
diabetic glucose tolerance; NFG = normal fasting glucose; IFG = impaired fasting 
glucose; DFG = diabetic fasting glucose.
table ii.      Number of subjects in each glucose 
category according to ADA and WHO 
diagnostic categories at baselineing 
to WHO criteria categories (mean 
(SD)) 
   confidence 
Variable Odds ratio p-value    interval
Age       1.05    0.11    0.99 - 1.11
Gender       0.58    0.42    0.15 - 2.03
Ethnic group       1.65    0.49    0.41 - 6.63
Systolic BP       1.01    0.51    0.98 - 1.04
Diastolic BP       1.03    0.30    0.98 - 1.08
Body mass index       0.10    0.99    0.88 - 1.13
Waist circumference        1.02    0.32    0.98 - 1.07
LDL cholesterol       1.09    0.80    0.58 - 2.05
HDL cholesterol       0.20    0.14    0.21 - 1.89
Total cholesterol       0.98    0.94    0.60 - 1.60
Triglycerides       2.49    0.14    0.75 - 8.31
HbA1c       3.31    0.00    1.56 - 7.05
ADA score       1.06    0.43    0.91 - 1.24
BP = blood pressure; LDL = low-density lipoprotein; HDL = high-density 
lipoprotein; ADA = American Diabetic Association.
table iii.     Univariate odds ratios of determi-
nants of diabetes mellitus
Fig. 1. ROC curves for prediction of abnormal glucose tolerance 
(m1= model 1 (ethnic group and age), m2 = model 2 (ethnic 
group, age, HDL, and triglycerides), m3 = model 3 (ethnic group, 
age, HDL, triglycerides and HbA1c), m4 = model 4 (ethnic group, 
age and HbA1c).




















diagnosis of DM.16 This perception is going to demand 
intensive reconsideration since this study showed an 
almost threefold increase in prevalence of DM using 
the OGTT compared with ADA fasting glucose (11.7% 
versus 4.2% respectively).
Most crucial is the evidence provided by the Decode 
study17 that fasting glucose alone does not identify 
individuals at increased risk of death associated 
with hyperglycaemia.  The OGTT provides additional 
prognostic information and enables detection 
of individuals with IGT who have the greatest 
attributable risk of death.17
Although clinical diagnosis requires a confirmatory 
test, in this study classification of patients was 
done on the basis of the first test. Follow-up glucose 
measurements were done, but not on all patients. Of 
the 14 patients diagnosed, 12 had at least either a 
repeat fasting glucose or an OGTT. One patient died 2 
days after admission and 1 gave an incorrect contact 
number and could not be contacted. Of the 5 patients 
diagnosed using the fasting ADA criteria, all had 
follow-up fasting glucoses done and the repeat results 
differed slightly. Three of the 5 were still classified 
as diabetic, while 2 were now classified as having 
NFG. In total, 12 repeat 2-hour glucose tests were 
performed. Seven of the 12 were still classified as 
diabetic; 3 were classified as IGT and the remaining 2 
were changed to NGT.
Even though the measurement of blood pressure was 
not used as an outcome measure it should be noted 
that measurements were done using a single cuff and 
only one reading was recorded.
In the study by Dinneen et al.,18 individuals with an 
initial FPG between 5.6 and 6.0 mmol/l demonstrated 
an approximately threefold higher risk of progressing 
to overt DM than individuals with an initial fasting 
glucose < 5.6 mmol/l. In this study, a fasting glucose 
of 5.6 mmol/l was found to yield optimal sensitivity 
and specificity.
In an article that looked at the impact of new 
diagnostic criteria for DM,19 the influence of age 
was not clear-cut and was only significant when 
comparing those ≥ 64 years of age.  These older people 
were more likely to be in the WHO group, in keeping 
with recent findings on older Americans, among 
whom 14.8% were diabetic on WHO criteria but only 
7.7% according to the ADA fasting criteria. Similar 
findings were found in this study, with the mean age 
of patients in the DGT group being 62 years.
In this study the 2-hour glucose value predicted 
DM 100% correctly. The second best predictor was 
HbA1c with an AUC of 0.76 and low sensitivity (21%) 
but a high specificity (99%).  Lowering the HbA1c 
to 5.3% would improve the sensitivity to 71%.  For 
the diagnosis of abnormal glucose tolerance other 
predictive variables, with the exception of fasting 
glucose, included age, ethnic group, HbA1c, HDL and 
triglycerides.   
Conclusion
The purpose of screening is to identify asymptomatic 
individuals who are likely to have DM, even though 
there are no randomised trials demonstrating benefits 
of early diagnosis.20 More telling are the most recent 
therapeutic  guidelines from the National Cholesterol 
Education Program which equate the cardiovascular 
risk associated with DM with that of patients with 
documented CAD.21 In summary, the results of this 
study show that the fasting ADA criteria defined fewer 
individuals as having abnormal glucose concentrations 
than the WHO criteria. The combination of 2-hour 
glucose and FPG provides more information than 
either alone. The measures of the metabolic syndrome 
did not prove to have any predictive power in 
diagnosing DM. However, the findings of this study 
indicate a need for future studies with larger sample 
sizes, and suggest that cardiologists should apply 
the same rigour in screening for DM as for the other 
modifiable risk factors.
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